Deanna Teoh

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer
    Deanna Teoh
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 122:467-72. 2011
  2. doi request reprint Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Departments of Medicine, and Medical Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC
    Int J Gynecol Cancer 24:218-25. 2014
  3. doi request reprint Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer
    Deanna Teoh
    Division of Gynecologic Oncology, Duke Cancer Institute, Durham, NC, USA
    Int J Gynecol Cancer 22:348-59. 2012
  4. pmc Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells
    Deanna Teoh
    Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Gynecol Oncol 121:187-92. 2011

Detail Information

Publications4

  1. ncbi request reprint Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer
    Deanna Teoh
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 122:467-72. 2011
    ..To evaluate the costs and effectiveness of thromboprophylaxis strategies following laparotomy for ovarian cancer...
  2. doi request reprint Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Departments of Medicine, and Medical Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, NC
    Int J Gynecol Cancer 24:218-25. 2014
    ..This study aimed to explore the activity of dasatinib in combination with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells...
  3. doi request reprint Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer
    Deanna Teoh
    Division of Gynecologic Oncology, Duke Cancer Institute, Durham, NC, USA
    Int J Gynecol Cancer 22:348-59. 2012
    ....
  4. pmc Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells
    Deanna Teoh
    Division of Gynecologic Oncology, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Gynecol Oncol 121:187-92. 2011
    ..To explore the activity of dasatinib alone and in combination with paclitaxel and carboplatin in ovarian cancer cells and to determine if dasatinib activity can be predicted based on evaluation of the SRC pathway...